Document is current
Any future updates will be listed below
-
Authors
Holmegaard, Lukas https://orcid.org/0000-0003-3528-0316
Jensen, Christer
Pedersen, Annie
Blomstrand, Christian
Blennow, Kaj
Zetterberg, Henrik
Jood, Katarina
Jern, Christina
-
Funding
Funding for this research was provided by:
Swedish Stroke Association
Swedish State Under the Agreement Between the Swedish Government and the County Councils (ALFGBG- 720931, ALFGBG-715986, ALFGBG-965417, ALFGBG-965328)
Swedish Research Council (2022-00732, 2018-02532, 2021-01114)
Swedish Alzheimer Foundation (AF-968270)
FP7 Ideas: European Research Council (681712)
Swedish Heart and Lung Foundation (20220184)
King Gustaf V:s and Queen Victoria´s Foundation
Agneta Prytz-Folke’s, and Gösta Folke’s Foundation
University of Gothenburg
- License Information
-
More Information
Article History
Received: 11 January 2024
Accepted: 9 July 2024
First Online: 13 July 2024
Competing interests
: H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. K.B. has served as a consultant or at advisory boards for Axon, Biogen, CogRx, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors declare no competing interests.
